Good question. Also, DT I wonder if you are able to share any...

Good question. Also, DT I wonder if you are able to share any interest from the clinicians for the all-comers trial which could give some comfort over the patient recruitment. The big risk in my mind is, if the clinicians are used to giving SOC to patients, how motivated will they be to suggest their patients to join the trial and add bisantrene to the regimen? At best they need to be convinced that there is no downside so the outcome is either unaffected or better for the patients. Since Race will sponsor the trial there is no additional cost to them? Or, will Race sponsor the SOC treatment along with Bis and hence there would be a motivation for those who may not be covered by their insurance to join the trial? Thanks.